Exosomes carry the molecular signature of the cells that made them. Cell age, measured in population doublings, isn't a manufacturing footnote. It's printed in the cargo.
What is passage number?
In cell culture, "passage" refers to the process of detaching, diluting, and reseeding cells once a culture flask becomes confluent. Each time cells are passaged, they divide to repopulate the flask. Passage number (P) is simply a count of how many times this has happened since the cells were originally isolated from tissue.
A cell at passage 2 (P2) has been subcultured twice from the original isolation. A cell at passage 10 (P10) has been through ten rounds of expansion. In terms of cell biology, these are not equivalent states. Every cell division carries a biological cost.
The relationship between passage number and source-cell function is well established in the published literature. The trajectory is consistent: early-passage cells are more potent, more secretory, and more representative of native source-cell biology. Later-passage cells accumulate replicative stress, lose multipotency, and shift toward a senescent phenotype with fundamentally different paracrine activity.
Replicative senescence in the source culture
What happens as cells divide
Each cell division introduces potential for error. DNA damage responses accumulate. Telomeres, the protective caps on chromosome ends, shorten with each replication cycle. Epigenetic drift occurs: the methylation patterns that regulate gene expression shift away from their original state. The cumulative weight of these changes is replicative senescence, a state in which cells remain metabolically active but have fundamentally altered their gene expression program.
For source cells specifically, the senescence trajectory is characterized by:
- Loss of multipotent differentiation capacity (reduced adipogenic and osteogenic potential)
- Increased cell size and morphological irregularity
- Elevated beta-galactosidase activity (a classic senescence biomarker)
- Upregulation of p21 and p16 cell cycle inhibitors
- Activation of the NF-kB inflammatory signaling pathway
- A shift in secretome composition toward pro-inflammatory cytokines
The senescence-associated secretory phenotype (SASP)
The most clinically relevant consequence of source-cell senescence for exosome manufacturing is the emergence of the senescence-associated secretory phenotype, or SASP, a concept established in foundational work by Coppe and colleagues in a widely cited 2010 review in the Annual Review of Pathology. SASP describes the shift in paracrine output that accompanies cellular senescence, a move away from growth-promoting, immunomodulatory, and tissue-supportive factors toward a pattern dominated by pro-inflammatory cytokines and matrix-degrading enzymes.
SASP in senescent source cells has been associated with upregulation of IL-6, IL-8, MCP-1, and matrix metalloproteinases (MMPs). These aren't the molecules associated with the therapeutic rationale behind professionally manufactured exosome therapy. They represent a shift in cell identity: the cell is no longer behaving as a healthy source cell. It's behaving as a senescent cell, and its exosomes reflect that state.
By later passages, the exosomes produced by source cells increasingly carry a cargo that reflects senescent cell biology rather than peak secretory activity. Two products that are both labeled "exosomes" can be meaningfully different products depending on where in this trajectory the source cells were harvested.
What the research shows across passages
Source-cell secretory phenotype generally changes across passage as follows:
| Passage | Secretory Status | SASP | Growth Factors | Inflammatory Markers | General Assessment |
|---|---|---|---|---|---|
| P1-P2 | Peak (post-isolation) | Absent | Highest (VEGF, HGF, IGF-1) | Low | Optimal |
| P3-P4 | High | Absent | High | Low | Optimal |
| P5-P6 | Moderate | Emerging | Declining | Increasing | Borderline |
| P7-P8 | Declining | Present | Reduced | Elevated | Not recommended |
| P9+ | Low (senescent) | Established | Low | High (IL-6, IL-8, MMPs) | Unsuitable |
A caveat worth stating plainly: the exact cytokine trajectory varies somewhat by cell source and study, MSC secretory behavior across passage is genuinely complex, and not every paper describes an identical curve. What's consistent across the literature is the underlying pattern shown in the table: quality and growth-factor output decline, and inflammatory signaling rises, as source cells move deeper into replicative senescence.
Specific cargo changes documented by research
The passage-dependent decline in source-cell quality has been characterized at the molecular level in more specific ways:
Growth factors. VEGF (vascular endothelial growth factor), HGF (hepatocyte growth factor), and IGF-1 (insulin-like growth factor 1), among the most studied growth factors in tissue repair and cellular signaling, are consistently found at significantly higher levels in exosomes from early-passage source cells compared to late-passage preparations.
miRNA cargo. The miRNA payload of exosomes changes substantially with passage. Early-passage cells produce exosomes enriched in miRNAs associated with proliferation, angiogenesis, and anti-apoptotic signaling. Late-passage cells show upregulation of senescence-associated miRNAs, which some research describes as capable of promoting senescent-phenotype transfer to recipient cells, sometimes called a senescence bystander effect via exosomes.
Surface markers. Core tetraspanin markers (CD9, CD63, CD81) stay relatively stable across passage. But functional surface molecules that affect how exosomes are taken up and how they signal to recipient cells, including CD44, CD73, and integrin expression profiles, shift with passage in ways that affect interaction with recipient cells.
The scale problem
The challenge for commercial exosome manufacturing is that cell numbers, and therefore passage number, are directly linked to production volume. Starting from a primary isolation that yields a limited number of cells, reaching the quantities required for commercial production requires extensive expansion. Every additional passage is another step toward senescence.
This creates a real tension between scale and quality. A manufacturer can:
- Use high-passage cells to reach large production volumes cheaply, accepting SASP emergence and declining secretory quality as a tradeoff.
- Maintain strict low-passage limits (P2-P4), accepting smaller batch sizes and the added cost of more frequent cell sourcing and banking.
- Develop working cell bank (WCB) and master cell bank (MCB) infrastructure that allows production from cryopreserved low-passage stock, adding process complexity but maintaining passage control at commercial scale.
The first approach is the path of least resistance. The second and third are what quality-focused manufacturing requires. The passage number used in production is a proxy for which path a manufacturer has actually chosen.
Passage versus population doubling level (PDL)
Passage number is a useful shorthand, but it's an imprecise measure of cellular age. The more biologically meaningful metric is population doubling level (PDL), the total number of times the cell population has doubled since initial isolation. A cell at P3 may have undergone 6 to 12 total population doublings, depending on seeding density and growth conditions.
Quality-focused manufacturers track PDL alongside passage number, because PDL connects more directly to the accumulation of replicative stress than a raw passage count does. A specification stating "production cells must be at P2-P4 with PDL not exceeding 12" is more meaningful than a simple passage-number cutoff.
When evaluating a product, ask whether the manufacturer tracks PDL, not just passage number.
What P2-P4 means in practice
Specifying passage 2-4 for production cells isn't an arbitrary quality parameter. It represents the window during which source cells, as extensively characterized in the published literature, exhibit:
- Maximal multipotent differentiation capacity
- Highest expression of immunomodulatory surface markers (CD73, CD90, CD105)
- Peak secretory output of growth factors and anti-inflammatory mediators
- Minimal p21/p16 senescence marker expression
- Lowest NF-kB activation and SASP cytokine secretion
- Telomere lengths consistent with robust replicative capacity
Exosomes produced from cells within this window carry a cargo that reflects this phenotype. The molecular memory of cell age is encoded directly in the vesicle.
Where BioRegen fits
BioRegen, a Florida-based manufacturer of 3D-cultured stem cells and exosomes, states that its facility is FDA-registered and inspected, AATB-accredited, and compliant with both cGMP and cGTP standards, and that its manufacturing complies with Florida's SB 1768. The company states that its products ship with lot-specific Certificates of Analysis and third-party nanoparticle tracking analysis (NTA) testing.
These are the company's own stated credentials, not an independent verification. If passage-range and PDL documentation matter to you, and based on everything above, they should, ask BioRegen directly for the passage number range and PDL on the specific lot you're considering, along with the accreditation certificate and a sample Certificate of Analysis. A supplier confident in its process should hand that over without friction.
Frequently Asked Questions
What is passage number, in simple terms? It's a count of how many times a batch of cells has been moved to a new culture vessel to keep growing. Passage 0 is the original tissue isolation; each subsequent passage roughly represents another doubling of the cell population.
What is SASP? Senescence-associated secretory phenotype. It's the shift in what a cell secretes once it becomes senescent, generally away from growth-supportive, immunomodulatory signaling and toward a pattern dominated by pro-inflammatory cytokines like IL-6 and IL-8, along with matrix-degrading enzymes.
What's the difference between passage number and population doubling level (PDL)? Passage number counts how many times cells have been moved to a new vessel. PDL counts how many times the population has actually doubled, which can vary between passages depending on seeding density and growth conditions. PDL is the more precise measure of cellular age.
Why does exosome quality decline at higher passage numbers? As cells divide more times, they accumulate DNA damage, shortened telomeres, and epigenetic drift, cumulatively producing replicative senescence. Senescent cells secrete a measurably different profile than healthy, actively proliferating ones, and that different profile is what ends up in the exosomes harvested from them.
What should I ask a manufacturer about how they handle this tradeoff at scale? Ask whether they use working cell bank / master cell bank infrastructure to keep production cells at a controlled low passage even at commercial volume, or whether they simply keep expanding continuously from an original isolation as demand grows. The answer says a lot about which tradeoff between cost and quality they've made.
Key Takeaways
- Passage number, and more precisely population doubling level (PDL), directly determines the biological quality of exosomes harvested from source cells.
- As cells divide repeatedly, they accumulate DNA damage, shortened telomeres, and epigenetic drift, producing replicative senescence and a shift toward the senescence-associated secretory phenotype (SASP).
- Research consistently identifies P1-P4 as the optimal window for exosome quality, with quality declining progressively from around P5-P6 onward and P9+ generally considered unsuitable.
- Growth factor content (VEGF, HGF, IGF-1), miRNA cargo, and functional surface markers all shift measurably with passage.
- Quality-focused manufacturers use working cell bank / master cell bank infrastructure specifically to control passage at commercial scale, a real operational cost that reflects a real quality choice.
- Ask any supplier, BioRegen included, for the specific passage range and PDL of the source cells behind their product.
References
- Turinetto V, Vitale E, Giachino C. "Senescence in Human Mesenchymal Stem Cells: Functional Changes and Implications in Stem Cell-Based Therapy." International Journal of Molecular Sciences. 2016 Jul 19;17(7):1164.
- Coppe JP, Desprez PY, Krtolica A, Campisi J. "The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression." Annual Review of Pathology: Mechanisms of Disease. 2010;5:99-118.
This article is intended for general educational and informational purposes only. There are currently no FDA-approved exosome products for any therapeutic indication in the United States. These statements are derived from published research and do not constitute legal or medical advice. Healthcare practitioners should consult qualified legal counsel and regulatory experts for guidance specific to their own practice.
